<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925209</url>
  </required_header>
  <id_info>
    <org_study_id>CBYM338B2203</org_study_id>
    <nct_id>NCT01925209</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients</brief_title>
  <acronym>RESILIENT</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability of i.v. BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility in Sporadic Inclusion Body Myositis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs
      placebo, when administered intravenously (i.v.), on physical function, muscle strength, and
      mobility in patients with sporadic inclusion body myositis (sIBM)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in 6 Minute Walking Distance Test (6MWD) meters to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 52 in the distance a patient can walk in a set timeframe. 6 Minute Walking Distance Test measures the distance (in meters) that a patient can walk in a 6 minute timeframe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in lean body mass (LBM) at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 52 in the total and appendicular lean body mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in quadriceps Quantitative Muscle Testing (QMT) at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 52 in quadriceps QMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient-Reported Physical Function at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 52 in a patient reported outcome instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Fall Events</measure>
    <time_frame>Baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Short Physical Performance Battery score at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to Week 52 in physical performance as measured by the Short Physical Performance Battery (SPPB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of different i.v. BYM338 doses</measure>
    <time_frame>Baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 6MWD meters to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dose-response relationship</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Sporadic Inclusion Body Myositis</condition>
  <arm_group>
    <arm_group_label>BYM338/bimagrumab High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the BYM338 High Dose administered via intravenous infusion from Day 1 to Week 52, and up to Week 104.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BYM338/bimagrumab Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the BYM338 Mid Dose administered via intravenous infusion from Day 1 to Week 52, and up to Week 104.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BYM338/bimagrumab Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the BYM338 Low Dose administered via intravenous infusion from Day 1 to Week 52, and up to Week 104.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 patients who meet all inclusion criteria and none of the exclusion criteria will be receive matching placebo administered via intravenous infusion from Day 1 to Week 52, and up to Week 104.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYM338/bimagrumab</intervention_name>
    <description>BYM338 will be administered via intravenous infusion to randomized patients beginning on Day 1 through Week 52, and up to Week 104.</description>
    <arm_group_label>BYM338/bimagrumab High Dose</arm_group_label>
    <arm_group_label>BYM338/bimagrumab Mid Dose</arm_group_label>
    <arm_group_label>BYM338/bimagrumab Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered via intravenous infusion to 60 randomized patients beginning on Day 1 through Week 52, and up to Week 104.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosed with sporadic inclusion body myositis; Must be able to walk (assistive aids
        allowed, including intermittent use of wheelchair);

        Exclusion Criteria:

        Must not have other conditions that significantly limit ability to move around; Must not
        be using corticosteroids. Must not have used systemic corticosteroid (at daily dose &gt;=10mg
        prednisone) for the past 3 months; Must meet cardiovascular requirements; Must not be
        pregnant or nursing; Must not have a chronic active infection (e.g., HIV, hepatitis B or
        C, tuberculosis, etc); Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>36 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neuromuscular Research Center, Contact: K. Sivakumar</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>University of California, Irvine Contact: N. Goyal</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>University of California, Davis Contact: B. Oskarsson</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>University of Miami Contact: D. Ascherman</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>University of Kansas Medical Center Contact: R. Barohn</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johns Hopkins University Contact: T. Lloyd</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colubus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oregon Health and Science University Contact: T. Marburger</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nerve &amp; Muscle Center of Texas Contact: A. Shaibani</last_name>
      <phone>888-669-6682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cauldfield</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokushima-city</city>
        <state>Tokushima</state>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kodaira-city</city>
        <state>Tokyo</state>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wakayama-city</city>
        <state>Wakayama</state>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden 2333 ZA</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sporadic inclusion body myositis,</keyword>
  <keyword>myositis,</keyword>
  <keyword>muscle wasting,</keyword>
  <keyword>controlled clinical trial,</keyword>
  <keyword>randomized,</keyword>
  <keyword>body mass,</keyword>
  <keyword>muscle function,</keyword>
  <keyword>strength,</keyword>
  <keyword>performance,</keyword>
  <keyword>physical function</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
